Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan, Cansu Karakaş, Iman Doostan, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 246

Showing 26-50 of 246 citing articles:

Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
Jessica L.F. Teh, Andrew E. Aplin
Clinical Cancer Research (2018) Vol. 25, Iss. 3, pp. 921-927
Open Access | Times Cited: 104
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Cristina Guarducci, Martina Bonechi, Matteo Benelli, et al.
npj Breast Cancer (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 104
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Nicole M. Kettner, Smruthi Vijayaraghavan, Merih Güray Durak, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 13, pp. 3996-4013
Open Access | Times Cited: 104
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Verena Wagner, Jesús Gil
Oncogene (2020) Vol. 39, Iss. 29, pp. 5165-5176
Open Access | Times Cited: 102
Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors
Zhifen Cui, Yu Zhang, Kai Xia, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 94
Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK 4/6 inhibitor palbociclib
Teemu P. Miettinen, Julien Peltier, Anetta Härtlová, et al.
The EMBO Journal (2018) Vol. 37, Iss. 10
Open Access | Times Cited: 93
Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer–stromal interaction and metastasis
Zilong Yan, Kenoki Ohuchida, Shuang Fei, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 93
Senolytics for Cancer Therapy: Is All that Glitters Really Gold?
Valerie J. Carpenter, Tareq Saleh, David A. Gewirtz
Cancers (2021) Vol. 13, Iss. 4, pp. 723-723
Open Access | Times Cited: 90
Molecular genetics and cellular events of K-Ras-driven tumorigenesis
Goodwin G. Jinesh, Vaishnavi Sambandam, Smruthi Vijayaraghavan, et al.
Oncogene (2017) Vol. 37, Iss. 7, pp. 839-846
Open Access | Times Cited: 89
CDK4/6 regulate lysosome biogenesis through TFEB/TFE3
Qiuyuan Yin, Youli Jian, Meng Xu, et al.
The Journal of Cell Biology (2020) Vol. 219, Iss. 8
Open Access | Times Cited: 88
Pan-cancer molecular analysis of the RB tumor suppressor pathway
Erik S. Knudsen, Ram Nambiar, Spencer R. Rosario, et al.
Communications Biology (2020) Vol. 3, Iss. 1
Open Access | Times Cited: 82
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Francisco Triana-Martínez, Marı́a Isabel Loza, Eduardo Domínguez
Cells (2020) Vol. 9, Iss. 2, pp. 346-346
Open Access | Times Cited: 81
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott Schoninger, Stacy W. Blain
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 1, pp. 3-12
Open Access | Times Cited: 79
Targeting Autophagy in Breast Cancer
Stefania Cocco, Alessandra Leone, Michela Piezzo, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7836-7836
Open Access | Times Cited: 78
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
Uzma Asghar, Ruhi Kanani, Rebecca Roylance, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 66
Targeting senescence as an anticancer therapy
Laura Bousset, Jesús Gil
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3855-3880
Open Access | Times Cited: 59
Role of autophagy in aging: The good, the bad, and the ugly
Siamak Tabibzadeh
Aging Cell (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 53
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Abeer J. Al-Qasem, Carla L. Alves, Sidse Ehmsen, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 43
Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy
Qitong Wu, Dipali Sharma
Cells (2023) Vol. 12, Iss. 8, pp. 1156-1156
Open Access | Times Cited: 31
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Fiona H. Zhou, Teesha Downton, Allegra Freelander, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 25
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, et al.
Cancer Research (2023) Vol. 83, Iss. 19, pp. 3264-3283
Open Access | Times Cited: 23
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression
J.M. Cejalvo Andujar, Francisco Ayala de la Peña, Mireia Margelí Vila, et al.
Cancer Drug Resistance (2025)
Open Access | Times Cited: 1
Microfluidic fabrication of lipid nanoparticles for co-delivery of siRNA and hydroxychloroquine: An engineered theranostic platform for enhanced breast cancer treatment
Lu Huang, Wenli Guo, Ting Zhao, et al.
Chemical Engineering Journal (2025), pp. 160172-160172
Open Access | Times Cited: 1
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions
Smruthi Vijayaraghavan, Stacy Moulder, Khandan Keyomarsi, et al.
Targeted Oncology (2017) Vol. 13, Iss. 1, pp. 21-38
Closed Access | Times Cited: 84

Scroll to top